Skip to main content

Carl E. Hock, Ph.D.

Senior Associate Dean for Research & Graduate School of Biomedical Sciences Professor

Rowan Medicine Building, Suite 2200


University of Louisville School of Medicine,
Department of Physiology and Biophysics, Ph.D., 1982

Research Interests

(Updated October 2014)

Work in this laboratory is directed toward the study of cardiovascular function under both normal and pathophysiologic conditions (i.e., circulatory shock, myocardial ischemia, etc.). Animal models of myocardial ischemia-reperfusion injury and acute endotoxemia are currently under investigation. Current work is focused on the effect of humoral mediators and inflammatory cells (i.e., angiotensin II, nitric oxide, eicosanoids, leukocytes, macrophages etc.) in the pathophysiology of ischemic states. We are also interested in the effect of modification of dietary lipid on cardiovascular function under both normal and pathophysiologic conditions. Diet-induced modification of cell membrane lipid structure can alter the cellular response to humoral mediators, receptor mediated processes, calcium binding and fatty acid mobilization. Current investigations include both nutritional and pharmacological interventions aimed at reducing both the formation and pro-ischemic actions of mediators of cardiovascular pathology.

Relevant Publications

  1. Desiderio MC, Mordecai RM, Walker J, Hock CE. Vascular Dysfunction in hypertension revealed by fourier analysis of aoritc blood flowCardiovasc Eng Technol, 4(2): 209-19, June 2013.
  2. Carsia RV, Weber H, McIlroy PJ, Hock CELong-term dietary lipid regimen alters adrenocortical function at the cellular level. Horm Metab Res, 40(12): 848-53, Dec 2008.
  3. Liu P, Xu B, Cavalieri TA, Hock CEInhibition of p53 by pifithrin-alpha reduces myocyte apoptosis and leukocyte transmigration in aged rat hearts following 24 hours of reperfusion. Shock, 30(5): 545-51, Nov 2008.
  4. Liu P, Xu B, Cavalieri TA, Hock CEPifithrin-alpha attenuates p53-mediated apoptosis and improves cardiac function in response to myocardial ischemia/reperfusion in aged rats. Shock, 26(6): 608-14, Dec 2006.
  5. Liu P, Xu B, Cavalieri TA, Hock CEAttenuation of antioxidative capacity enhances reperfusion injury in aged rat myocardium after MI/R. Am J Physiol Heart Circ Physiol, 287(6): H2719-27, Dec 2004.
  6. Liu P, Xu B, Cavalieri TA, Hock CEAge-related difference in myocardial function and inflammation in a rat model of myocardial ischemia-reperfusion. Cardiovasc Res, 56(3): 443-53, Dec 2002.
  7. Liu P, Xu B, Forman LJ, Carsia R, Hock CEL-NAME enhances microcirculatory congestion and cardiomyocyte apoptosis during myocardial ischemia-reperfusion in rats. Shock, 17(3): 185-92, Mar 2002.
  8. Liu P, Xu B, Hock CE. Inhibition of nitric oxide synthesis by L-name exacerbates acute lung injury induced by hepatic ischemia-reperfusion. Shock, 16(3): 211-7, Sep 2001.
  9. Yin K, Hock CE, Lai PS, Ross JT, Yue G. Role of interferon-gamma in lung inflammation following cecal ligation and puncture in rats. Shock, 12(3): 215-21, Sep 1999.
  10. Liu P, Xu B, Hock CE, Nagele R, Sun FF, Wong PY. NO modulates P-selectin and ICAM-1 mRNA expression and hemodynamic alterations in hepatic I/R. Am J Physiol, 275(6 Pt 2): H2191-8, Dec 1998.
  11. Yin K, Hock CE, Tahamont M, Wong PY. Time-dependent cardiovascular and inflammatory changes in acute endotoxemia. Shock, 9(6): 434-42, June 1998.
  12. Liu P, Hock CE, Nagele R, Wong PY. Formation of nitric oxide, superoxide, and peroxynitrite in myocardial ischemia-reperfusion injury in rats. Am J Physiol, 272(5 Pt 2):H2327-36, May 1997.
  13. Hock CE, Yin K, Yue G, Wong PY. Effects of inhibition of nitric oxide synthase by aminoguanidine in acute endotoxemia. Am J Physiol, 272(2 Pt 2): H843-50, Feb 1997.
  14. Carsia RV, Forman D, Hock CE, Nagele RG, McIlroy PJ. Lead alters growth and reduces angiotensin II receptor density of rat aortic smooth muscle cells. Proc Soc Exp Biol Med, 210(2): 180-90, Nov 1995.
  15. Forman LJ, Hock CE, Harwell M, Estilow-Isabell S. Comparison of the effects of immobilization and pressure overload induced cardiac hypertrophy on immunoreactive beta-endorphin. Life Sci, 57(22): 2041-7, Oct 1995.
  16. Patel JP, Beck LD, Briglia FA, Hock CEBeneficial effects of combined thromboxane and leukotriene receptor antagonism in hemorrhagic shock. Crit Care Med, 23(2): 231-7, Feb 1995.
  17. Forman LJ, Hock CE, Harwell M, Estilow-Isabell S. The results of exposure to immobilization, hemorrhagic shock, and cardiac hypertrophy on beta-endorphin in rat cardiac tissue. Proc Soc Exp Biol Med, 206(2):124-9, Jun 1994.
  18. Hock CE, Beck LD, Papa LA. Peptide leukotriene receptor antagonism in myocardial ischaemia and reperfusion. Cardiovasc Res, 26(12):1206-11, Dec 1992.